Literature DB >> 12781422

Survival among Chinese women with lung cancer in Singapore: a comparison by stage, histology and smoking status.

Y K Tan1, T C Wee, W P Koh, Y T Wang, P Eng, W C Tan, A Seow.   

Abstract

Lung cancer generally carries a poor prognosis and the determinants of survival have been of interest. However, survival estimates in Asian populations are scarce. This study describes survival rates and their determinants in Singapore Chinese women, a primarily non-smoking population. Three hundred and twenty-six Chinese women, diagnosed with primary lung carcinoma in three major hospitals in Singapore between April 1996 and December 1998, were followed up till 31 December 2000. The Kaplan-Meier method was used for survival analysis. Two hundred and eighty (85.7%) died from the disease during follow-up. The median survival time was 0.7 years and the three-year survival was 15.8%. These survival rates are similar to those of Western populations, and they provide a basis for examining trends over time. Age at diagnosis was an independent prognostic factor [adjusted hazard ratio (relative risk) 1.4, 95% confidence intervals (CI) 1.1-1.9 for women above 65 years relative to younger women]. Most (70.5%) tumours were stage III/IV at diagnosis. Three-year survival ranged from 72% among patients with stage I tumours to 7% for stage IV tumours. Overall, there was no survival difference among different histological types in all stages combined. When limited to stages I and II cancers, adenocarcinomas were associated with a better outcome relative to other histological subtypes combined (adjusted relative risk 0.4, 95% CI 0.1-1.0). Smoking was an independent risk factor (adjusted relative risk 1.3, 95% CI 1.0-1.8). Nevertheless, non-smokers comprised 57.4% of this series, highlighting the importance of increased awareness among health professionals and the public that lung cancer is not only a disease of smokers. The high proportion of late-stage tumours in this study and the impact of disease stage on outcome underline the importance of early detection in improving survival of lung cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12781422     DOI: 10.1016/s0169-5002(03)00038-2

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

Review 1.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

2.  Survival of primary lung cancer patients in Brunei Darussalam, 1987-2012.

Authors:  Lin Naing; Amalina Abdullah; Syafiq Abdullah; Nurolaini Kifli
Journal:  Ann Transl Med       Date:  2017-03

3.  Lung cancers unrelated to smoking: characterized by single oncogene addiction?

Authors:  Kenichi Suda; Kenji Tomizawa; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Int J Clin Oncol       Date:  2011-06-08       Impact factor: 3.402

4.  Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.

Authors:  Yelena Y Janjigian; Kevin McDonnell; Mark G Kris; Ronglai Shen; Camelia S Sima; Peter B Bach; Naiyer A Rizvi; Gregory J Riely
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

5.  Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.

Authors:  Jared M Weiss; Liza C Villaruz; Jonathon O'Brien; Anastasia Ivanova; Carrie Lee; Juneko Grilley Olson; Gregory Pollack; Richard Gorman; Mark A Socinski; Thomas E Stinchombe
Journal:  Clin Lung Cancer       Date:  2015-12-17       Impact factor: 4.785

Review 6.  Lung cancer in never smokers: molecular profiles and therapeutic implications.

Authors:  Charles M Rudin; Erika Avila-Tang; Curtis C Harris; James G Herman; Fred R Hirsch; William Pao; Ann G Schwartz; Kirsi H Vahakangas; Jonathan M Samet
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

7.  Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study.

Authors:  M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2018-10-19       Impact factor: 3.405

8.  Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer.

Authors:  Daniel Misch; Torsten Blum; Christian Boch; Timo Weiss; Catharina Crolow; Sergej Griff; Thomas Mairinger; Torsten T Bauer; Jens Kollmeier
Journal:  Diagn Pathol       Date:  2015-04-02       Impact factor: 2.644

9.  Important prognostic factors for the long-term survival of lung cancer subjects in Taiwan.

Authors:  Tai-An Chiang; Ping-Ho Chen; Pei-Fen Wu; Tsu-Nai Wang; Po-Ya Chang; Albert Min-Shan Ko; Ming-Shyan Huang; Ying-Chin Ko
Journal:  BMC Cancer       Date:  2008-11-07       Impact factor: 4.430

Review 10.  Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.

Authors:  Meng-Jiao Li; Qing He; Mei Li; Feng Luo; Yong-Song Guan
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.